Aeglea BioTherapeutics, Inc. (AGLE)
After hours:
| Previous close | 0.3218 |
| Open | 0.3214 |
| Bid | 0.3103 x 1300 |
| Ask | 0.3500 x 900 |
| Day's range | 0.3096 - 0.3410 |
| 52-week range | 0.3000 - 3.1700 |
| Volume | |
| Avg. volume | 330,166 |
| Market cap | 21.58M |
| Beta (5Y monthly) | 1.71 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.9400 |
| Earnings date | 03 May 2023 - 08 May 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 2.50 |
- PR Newswire
Aeglea BioTherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced the company granted non-qualified equity awards to four new employees with a grant date of March 17, 2023, as equity inducement awards outside of the company's 2016 Equity Incentive Plan, but under the terms of the company's 2018 Equity Inducement Plan. The awards were granted as material i
- Zacks
Aeglea Biotherapeutics (AGLE) Reports Q4 Loss, Lags Revenue Estimates
Aeglea (AGLE) delivered earnings and revenue surprises of 10% and 1.18%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- PR Newswire
Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Program Updates
Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced financial results for the fourth quarter and full year 2022, and provided program updates.
